Compare ADMA Biologics Inc (ADMA) vs Avantis International Small Cap Value ETF (AVDV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Avantis International Small Cap Value ETF — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Avantis International Small Cap Value ETF trades at $102.77. The key difference: Avantis International Small Cap Value ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | AVDV | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Sector/Thematic |
52-Week High | $20.38 | $110.40 |
52-Week Low | $7.60 | $80.02 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
AVDV trades at $105.77, up 1.29% today, with a bullish technical signal from moving averages. The ETF focuses on international small-cap value stocks, delivering strong performance with 35% gains highlighted in recent coverage. Dividend payments provide additional investor returns, with the next $1.39 distribution scheduled for June 2026.
Outlook remains positive given international small-cap value momentum, though cyclical sector exposure and reliance on regional factors present risks. Structural alpha concerns noted by analysts suggest monitoring performance drivers beyond broad market trends for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Avantis International Small Cap Value ETF
AVDV is an actively managed ETF that targets small-cap value companies in developed markets outside the United States. It uses a systematic, rules-based process to identify firms trading at low valuations with high profitability, aiming to capture the 'size' and 'value' premiums while maintaining broad diversification.
Read more on AVDV →
